Combination of Yondelis (ET-743) and oxaliplatin in experimental ovarian cancer.

被引：0
|
作者：
Erba, E
Colombo, T
Ubezio, P
Ferrarese, L
Matera, G
Falcioni, C
Faircloth, G
Jimeno, J
D'Incalci, M
机构：
[1] IM Mario Negri, Milan, Italy
[2] PharmaMar R&D, Boston, MA USA
[3] PharmaMar R&D, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [21] A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
    Zelek, L.
    Yovine, A.
    Brain, E.
    Turpin, F.
    Taamma, A.
    Riofrio, M.
    Spielmann, M.
    Jimeno, J.
    Misset, J. L.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1610 - 1614
  • [22] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
    Esther F. A. Brandon
    Rolf W. Sparidans
    Kees-Jan Guijt
    Sjoerd Löwenthal
    Irma Meijerman
    Jos H. Beijnen
    Jan H. M. Schellens
    Investigational New Drugs, 2006, 24 : 3 - 14
  • [23] ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
    Duan, Zhenfeng
    Choy, Edwin
    Harmon, David
    Yang, Cao
    Ryu, Keinosuke
    Schwab, Joseph
    Mankin, Henry
    Hornicek, Francis J.
    PLOS ONE, 2009, 4 (09):
  • [24] Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia
    Hing, J.
    Perea-Ruixo, J. J.
    Stuyckens, K.
    Soto-Matos, A.
    Lopez-Lazaro, L.
    Zannikos, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 130 - 143
  • [25] In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
    Brandon, EFA
    Sparidans, RW
    Guijt, KJ
    Löwenthal, S
    Meijerman, I
    Beijnen, JH
    Schellens, JHM
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (01) : 3 - 14
  • [26] Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
    Erba, E
    Bergamaschi, D
    Bassano, L
    Ronzoni, S
    Di Liberti, G
    Muradore, I
    Vignati, S
    Faircloth, G
    Jimeno, J
    D'Incalci, M
    BRITISH JOURNAL OF CANCER, 2000, 82 (10) : 1732 - 1739
  • [27] The antitumor agent Ecteinascidin-743 (ET-743, Yondelis) inhibits signal-activated transcription by reversing RNAPII and coregulator recruitment cycles.
    Solier, Corinne
    Ianculescu, Irina
    Kaplan, Roman
    Forman, Barry M.
    TUMOR BIOLOGY, 2006, 27
  • [28] ZNF93 overexpression is associated with ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) resistance in human cancer cell lines
    Duan, Zhenfeng
    Choy, Edwin
    Yang, Cao
    Schwab, Joseph
    Del Maria, Carmen
    Mankin, Henry
    Hornicek, Francis
    CANCER RESEARCH, 2009, 69
  • [29] Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat
    Donald, S
    Verschoyle, RD
    Greaves, P
    Gant, TW
    Colombo, T
    Zaffaroni, M
    Frapolli, R
    Zucchetti, M
    D'Incalci, M
    Meco, D
    Riccardi, R
    Lopez-Lazaro, L
    Jimeno, J
    Gescher, AJ
    CANCER RESEARCH, 2003, 63 (18) : 5902 - 5908
  • [30] Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis)
    Van Oosterom, Alian
    Makl, Robert
    Taron, Miquel
    Sciot, Raf
    Fernandez Sousa-Faro, Jose Maria
    Nieto, Antonio
    Jimeno, Jose
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2004, 15 : 197 - 197
12345